Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc’h, Darren A.E. Cross, Maria Emanuela Cuomo et al.|Molecular Cancer Therapeutics|2018Cited by 113
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung CancerCaroline E. McCoach, Karen Kelly, Ai‐Ming Yu et al.|JCO Precision Oncology|2021Cited by 35
Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.Jonathan W. Riess, Darren A.E. Cross, Nicolas Floc’h et al.|Journal of Clinical Oncology|2017Cited by 8